CVRdatabase
Menu

OncoSpear ApS

Private limited companyCVR 42093734HinnerupActive

OncoSpear ApS is a private limited company, based in Hinnerup, active in manufacture of pharmaceutical preparations, founded in 2021. The company made a loss in both 2024 and 2025, most recently DKK 822k. Equity fell to DKK 570k in 2025.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profitDKK 2.9m+162.9% vs. 2024
Net profit−DKK 822k+87.3% vs. 2024
EquityDKK 570k−59.1% vs. 2024
Employees8latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss got smaller: from DKK 6.5m to DKK 822k (2024 → 2025).
  • Equity fell 59% (2024 → 2025), to DKK 570k.

Employees

  • 1 more employees than a year earlier: 8 (07/2026) against 7 (07/2025).

Management and owners, last 24 months

  • New in management: Geert Gilbert Tackaert (director, 30/10/2024).
  • Stepped down: Holger Jon Møller (board member, 30/10/2024), Anders Etzerodt (board member, 30/10/2024) and Toby Lawrence (board member, 30/10/2024) (+3).

Registrations, last 24 months

  • 07/01/2026: Moved to Lucernevej 2, 8382 Hinnerup
  • 10/06/2025: Moved to Sanatorievej 8, 5600 Faaborg

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2021–2025 · amounts in DKK thousand

Equity and net profit

−DKK 8m−DKK 6m−DKK 4m−DKK 2mDKK 0DKK 2mDKK 4mDKK 6mDKK 8m20212022202320242025
EquityNet profit
Financial figures for OncoSpear ApS
20212022202320242025Change
Revenuenot statednot statednot statednot statednot stated–
Gross profit−26−640−5,396−4,6522,927+162.9%
Operating profit (EBIT)–−1,228−8,147−8,041−1,005+87.5%
Profit before tax−26−1,228−8,147−8,045−1,041+87.1%
Net profit−26−1,090−6,694−6,461−822+87.3%
Total assets337,5109,2533,2519,511+192.6%
Equity247,1127,8531,392570−59.1%
Liabilities103971,4001,8598,941+381%
Cash and cash equivalents337,3007,4141,0492,547+142.9%
Average number of employees––5550%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 6m−DKK 4m−DKK 2mDKK 0DKK 2m20212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 5 years in a row

    Net result has been negative in 2021–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

  • Equity fell sharply

    Equity fell 59% from 2024 to 2025 (DKK 1.4m to DKK 570k).

    How is this calculated?

    Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.

  • Low equity ratio

    Equity makes up 6% of total assets in 2025.

    How is this calculated?

    Equity ÷ total assets is below 10% in the latest annual report. Banks, insurers and some industries naturally have a low ratio.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

5 financial years
Annual reports for OncoSpear ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202530/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202413/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202327/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202229/06/2023The companyPDFXBRL
202101/02/2021 – 31/12/202131/05/2022The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
0246808/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profitDKK 2.9mNo. 28 of 57
Better than 52% of the companies in the industry
EquityDKK 570kNo. 42 of 59
Better than 29% of the companies in the industry
Number of employees8No. 33 of 59
Better than 45% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bnHere
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 23,117of 69,742
Better than 67%
No. 40,624of 69,964
Better than 42%
Same industry and fewer than 20 employees37 companies in the comparison
No. 11of 36
Better than 71%
No. 23of 37
Better than 39%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 13,307of 33,588
Better than 60%
No. 19,097of 33,687
Better than 43%
All companies of type ApS66,508 companies in the comparison
No. 22,788of 66,379
Better than 66%
No. 36,531of 66,505
Better than 45%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. OncoSpear ApSDKK 2.9m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. OncoSpear ApS−DKK 822k
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. OncoSpear ApSDKK 570k
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. OncoSpear ApS8
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Spica Therapeutics100%
OncoSpear ApS

Management

2 active registrations

Executive management

Executive management at OncoSpear ApS
NameRoleAppointed
Niels Jonas Heilskov GraversenDirector01/02/2021
Geert Gilbert TackaertDirector30/10/2024
Founders
Moestrup Holding 2007 ApS, Møller Holding 2007 ApS, Phideas ApS, DeLiver Pharma ApS, Etze Holding ApS, Toby Lawrence
Former management (9)
Former management at OncoSpear ApS
NameRoleAppointedResigned
Jens Kristian DamsgaardBoard member01/02/202127/06/2023
Søren Kragh MoestrupChair of the board01/02/202101/01/2023
Holger Jon MøllerBoard member01/02/202130/10/2024
Anders EtzerodtBoard member01/02/202130/10/2024
Toby LawrenceBoard member01/02/202130/10/2024
Alexander Bharmal DemoulinBoard member30/09/202230/10/2024
Debora Catharina DumontBoard member30/09/202201/01/2023
Søren Kragh MoestrupBoard member02/01/202330/10/2024
Debora Catharina DumontChair of the board02/01/202330/10/2024

Signing rule: Selskabet tegnes af den samlede direktion

Address and production units

1 active production units

Lucernevej 2
8382 Hinnerup

Favrskov Municipality · Postcode 8382

Production units
Production unitAddressEmployeesP number
OncoSpear ApSLucernevej 2, 8382 Hinnerup81026768736

Purpose

Selskabets formål er at udvikle, markedsføre, licensere og sælge lægemidler, herunder at udvikle en forskningsplatform, der vil blive brugt til at identificere receptorer, der kan binde til lægemiddelkandidater, samt dermed beslægtede aktiviteter.

The purpose is quoted from the register in Danish.

Changes year by year

66 registered events
20262 changesaccounts 1 · address 1
  • Annual report for 2025 published
  • Moved to Lucernevej 2, 8382 Hinnerup
20252 changesaccounts 1 · address 1
  • Annual report for 2024 published
  • Moved to Sanatorievej 8, 5600 Faaborg
202416 changesmanagement 7 · ownership 8 · accounts 1
  • Geert Gilbert Tackaert appointed director
  • Søren Kragh Moestrup stepped down as board member
  • Debora Catharina Dumont stepped down as chair of the board
  • Alexander Bharmal Demoulin stepped down as board member
  • Anders Etzerodt stepped down as board member
  • Holger Jon Møller stepped down as board member
  • Toby Lawrence stepped down as board member
  • SPICA THERAPEUTICS registered as owner (100%)
  • Bioqube Factory Fund I CommV is no longer registered as owner
  • MOESTRUP HOLDING 2007 ApS is no longer registered as owner
  • PHIDEAS ApS is no longer registered as owner
  • MØLLER HOLDING 2007 ApS is no longer registered as owner
  • DeLiver Pharma ApS is no longer registered as owner
  • Etze Holding ApS is no longer registered as owner
  • Toby Lawrence is no longer registered as owner
  • Annual report for 2023 published
202316 changescapital 2 · ownership 8 · accounts 1 · management 5
  • Share capital changed from 97,778 DKK to 108,889 DKK
  • Bioqube Factory Fund I CommV registered as owner (50%)
  • Bioqube Factory Fund I CommV is no longer registered as owner
  • Annual report for 2022 published
  • Share capital changed from 86,667 DKK to 97,778 DKK
  • Jens Kristian Damsgaard stepped down as board member
  • MOESTRUP HOLDING 2007 ApS registered as owner (5%)
  • PHIDEAS ApS registered as owner (5%)
  • MØLLER HOLDING 2007 ApS registered as owner (5%)
  • MOESTRUP HOLDING 2007 ApS is no longer registered as owner
  • MØLLER HOLDING 2007 ApS is no longer registered as owner
  • PHIDEAS ApS is no longer registered as owner
  • Søren Kragh Moestrup appointed board member
  • Debora Catharina Dumont appointed chair of the board
  • Debora Catharina Dumont stepped down as board member
  • Søren Kragh Moestrup stepped down as chair of the board
202217 changescapital 1 · management 2 · ownership 13 · accounts 1
  • Share capital changed from 50,000 DKK to 86,667 DKK
  • Alexander Bharmal Demoulin appointed board member
  • Debora Catharina Dumont appointed board member
  • DeLiver Pharma ApS registered as owner (10%)
  • MOESTRUP HOLDING 2007 ApS registered as owner (10%)
  • MØLLER HOLDING 2007 ApS registered as owner (10%)
  • PHIDEAS ApS registered as owner (10%)
  • Etze Holding ApS registered as owner (5%)
  • Toby Lawrence registered as owner (5%)
  • Bioqube Factory Fund I CommV registered as owner (33.33%)
  • MØLLER HOLDING 2007 ApS is no longer registered as owner
  • Toby Lawrence is no longer registered as owner
  • Etze Holding ApS is no longer registered as owner
  • MOESTRUP HOLDING 2007 ApS is no longer registered as owner
  • DeLiver Pharma ApS is no longer registered as owner
  • PHIDEAS ApS is no longer registered as owner
  • Annual report for 2021 published
202113 changesfounded 1 · management 6 · ownership 6
  • Registered as OncoSpear ApS
  • Jens Kristian Damsgaard appointed board member
  • Søren Kragh Moestrup appointed chair of the board
  • Anders Etzerodt appointed board member
  • Holger Jon Møller appointed board member
  • Niels Jonas Heilskov Graversen appointed director
  • Toby Lawrence appointed board member
  • MØLLER HOLDING 2007 ApS registered as owner (15%)
  • Toby Lawrence registered as owner (15%)
  • Etze Holding ApS registered as owner (15%)
  • MOESTRUP HOLDING 2007 ApS registered as owner (15%)
  • DeLiver Pharma ApS registered as owner (25%)
  • PHIDEAS ApS registered as owner (15%)

Related companies

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction